Pasithea Therapeutics Corp. (NASDAQ:KTTA) Sees Significant Growth in Short Interest

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the recipient of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 24,200 shares, a growth of 374.5% from the November 15th total of 5,100 shares. Based on an average trading volume of 934,600 shares, the days-to-cover ratio is presently 0.0 days. Currently, 2.4% of the company’s shares are short sold.

Pasithea Therapeutics Stock Down 6.5 %

Shares of NASDAQ:KTTA traded down $0.19 during trading on Wednesday, reaching $2.75. 20,070 shares of the stock were exchanged, compared to its average volume of 270,216. Pasithea Therapeutics has a 12-month low of $2.70 and a 12-month high of $9.60. The firm’s 50-day moving average price is $3.73 and its 200 day moving average price is $4.59.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.